Android app on Google Play

Notable Analyst Rating Changes 11/21: (PENN) (THOR) (SKX) Upgraded; (HTWR) (EV) (ICA) Downgraded

November 21, 2012 10:27 AM EST Send to a Friend
Get Alerts PENN Hot Sheet
Price: $13.04 -2.61%

Rating Summary:
    11 Buy, 10 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 10 | New: 20
Trade PENN Now!
Join SI Premium – FREE
UPGRADES
Lazard Capital upgrades Penn National Gaming (Nasdaq: PENN) from Neutral to Buy.

Wells Fargo boosts Thoratec (Nasdaq: THOR) from Market Perform to Outperform, lifting its valuation range from $34 to $35 to a new range $41 to $42. Click Here for more color.

Susquehanna raises Skechers USA (NYSE: SKX) from Neutral to Positive.

Sandler O’Neill lifts FirstMerit Corporation (Nasdaq: FMER) from Hold to Buy.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
Heartware Int'l (Nasdaq: HTWR) lowered by two firms Wednesday:
  • Wells Fargo from Outperform to Market Perform and lowers its valuation range from $97 to $99 down to a range of $88 to $89. Click Here for more color;

  • UBS from Buy to Neutral.

Citi downgrades Eaton Vance (NYSE: EV) from Neutral to Sell.

UBS reduces Empresas ICA SA (NYSE: ICA) from Buy to Neutral.

Wells Fargo lowers St. Jude Medical (NYSE: STJ) from Outperform to Market Perform and cut its price target range from $49 to $50 to a range of $25 to $36. Click Here for more color.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
LINN Energy (Nasdaq: LINE) started by a handful today:
  • BofA/Merrill Lynch at Neutral and $40 price target;

  • Goldman Sachs at Neutral and $47 target. Click Here for more color;

  • Barclays with an Overweight and $44 target; and

  • UBS at Buy and $43 target.

RBC Capital initiates Infinity Pharmaceutical (Nasdaq: INFI) with an Outperform and $28 price target.

Linn Co, LLC (Nasdaq: LNCO) also started by a slew of analysts Wednesday:
  • Baird at Outperform and $48 target;

  • Goldman Sachs with a Neutral and target of $44. Click Here for more color;

  • Credit Suisse at Neutral and $37.50 target;

  • UBS with a Buy and $41 target; and

  • BofA/Merrill Lynch with a Neutral.

Brean Capital starts Biogen (Nasdaq: BIIB) with a Buy and $184 target. Click Here for more color.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.




You May Also Be Interested In


Related Categories

Analyst Comments, Special Reports

Related Entities

Credit Suisse, UBS, Citi, Merrill Lynch, Robert W Baird, Bank of America, Lazard, RBC Capital, Barclays, Susquehanna International Group of Companies, Notable Analyst Rating Changes, Wells Fargo

Add Your Comment